Does HDAC inhibition reverse preexisting diastolic dysfunction and block extracellular matrix remodeling?
HDAC inhibition shows potential to reverse diastolic dysfunction by targeting covert extracellular matrix remodeling, highlighting the need for diverse methodologies beyond standard stains to evaluate cardiac fibrosis.
These findings demonstrate the potential of HDAC inhibition as a therapeutic intervention to reverse existing DD and establish blockade of extracellular matrix remodeling as a second mechanism by which HDAC inhibitors improve ventricular filling. Our data reveal the existence of pathophysiologically relevant covert or hidden cardiac fibrosis that is below the limit of detection of histochemical stains such as picrosirius red, highlighting the need to evaluate fibrosis of the heart using diverse methodologies.
Travers et al. (Mon,) studied this question.